<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190944</url>
  </required_header>
  <id_info>
    <org_study_id>8175</org_study_id>
    <secondary_id>B3D-MC-GHCN</secondary_id>
    <nct_id>NCT00190944</nct_id>
  </id_info>
  <brief_title>Effects of Teriparatide on Distal Radius Fracture Healing</brief_title>
  <official_title>Effects of Teriparatide on Distal Radius Fracture Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      Effects of Teriparatide on Distal Radius Fracture Healing
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to radiographic healing</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>There are no secondary outcomes for this trial</measure>
  </secondary_outcome>
  <enrollment>105</enrollment>
  <condition>Colles' Fracture</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Ambulatory, postmenopausal, women 45 to 85 years of age. Postmenopausal is defined as at
        least 2 years without regular menses

        Sustained a unilateral, dorsally angulated fracture of the distal radius within 10 days

        Received conservative treatment of her distal radius fracture, including closed reduction
        and immobilization device (such as cast, splint, or brace)

        Free of severe or chronically disabling conditions other than a distal radius fracture as
        determined by the investigator

        Without language barrier, cooperative, expected to return for all follow-up procedures, and
        has given informed consent before entering the study and after being informed of the risks,
        medications and procedures to be used in the study.

        In the opinion of the investigator, the patient is willing to be trained and use the
        pen-injector daily, is able to satisfactorily use a pen-type injection delivery system, or
        is willing to receive daily subcutaneous injections from a care partner who has been
        trained to use the pen injector

        Exclusion Criteria:

        Increased baseline risk of osteosarcoma

        History of a malignant neoplasm in the 5 years prior to visit 2, with the exception of
        superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been
        definitely treated

        Have currently known, suspected, or history of other diseases that affect bone metabolism
        other than postmenopausal osteoporosis or cause secondary osteoporosis that has been
        clinically active in the 1 year prior to visit 2

        Have elevated serum calcium values

        Active liver disease or clinical jaundice

        History of symptomatic nephro-or urolithiasis in the 2 years prior to visit 2

        Previous fractures or bone surgery in the currently fractured distal forearm

        Joint disease such as rheumatoid arthritis or disabling osteoarthritis that clearly affect
        the function of the wrist and/or hand of the injured arm

        Requirement for chronic treatment with nonsteroidal anti-inflammatory drugs defined as more
        than 3 consecutive months of any NSAID treatment

        Treatment with:

        Oral bisphosphonates for more than 18 months during the prior 3 years, or have received any
        oral or intravenous biphosphonate therapy within the last 2 months prior to screening.

        Oral strontium ranelate for any duration

        Systemic corticosteroids for more than 30 days (total) in the 6 months prior to visit 2, or
        any systemic corticosteroid dose in the 1 month prior to visit 2. Ophthalmic, oric,
        topical, or nasally inhaled corticosteroid therapy may be used without these restrictions.

        Fluoride at therapeutic doses (greater than or equal to 20mg/day) for more than 3 months
        during the last 2 years or for more than a total of 2 years, or any dosages within the 6
        months prior to visit 2.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64461</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>PL-02-0500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>0500988</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Linkoping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 10, 2007</last_update_submitted>
  <last_update_submitted_qc>October 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Radius Fractures</mesh_term>
    <mesh_term>Colles' Fracture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

